In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
News|Articles|August 6, 2025
OncLive’s July EMA Regulatory Recap: Key EU Approvals in Oncology
Author(s)Courtney Flaherty
Fact checked by: Chris Ryan
Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.
Advertisement
Advertisement
Stay up-to-date with the latest regulatory milestones shaping cancer care across Europe. Below is your guide to all oncologic therapies approved by the European Commission (EC) in July 2025, including the pivotal clinical data behind each decision. Read on to learn more!
Related to this article
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Advertisement
Advertisement